Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda

Ashwani K. Singal, Krishna V.R. Venkata, Sarat Jampana, Fakhar Ul Islam, Karl E. Anderson

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Background Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. Materials and Methods A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients). Results Before starting HCV treatment, PCT was in complete remission in 16, partial remission in 2, unknown status in 2 and active in 2 instances. PCT relapsed during therapy 6 times (all interferon-based regimens and 2 including telaprevir), 4 requiring treatment interruption. Treatment was interrupted for reasons other than PCT relapse in 2 patients treated with interferon-based regimens. To prevent PCT recurrence, hydroxychloroquine was continued during HCV therapy 6 times (3 interferon regimens, 2 ribavirin regimens without interferon and 1 DAA alone). Twelve patients achieved sustained viral response, 3 with interferon regimens and 9 with DAA. Two patients with active PCT were treated with DAA, with reduction of plasma porphyrins in 1 and normalization in the other at the end of HCV therapy. Conclusions HCV treatment regimens including interferon or ribavirin may precipitate PCT relapse. Hydroxychloroquine may be useful to prevent such relapses. In this limited experience, DAA were not associated with PCT relapse. Studies are needed to examine DAA as a primary PCT treatment in HCV-infected patients.

Original languageEnglish (US)
Pages (from-to)523-528
Number of pages6
JournalAmerican Journal of the Medical Sciences
Issue number6
StatePublished - Jun 1 2017


  • Direct-acting antivirals
  • Hepatitis C
  • Interferon
  • Porphyria

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda'. Together they form a unique fingerprint.

Cite this